Macropinocytosis-selective monobody-drug conjugate
Unbound protein-drug conjugates using an FN3 domain for macropinocytosis targeting address the ineffectiveness and toxicity of current KRas cancer therapies by providing targeted and safer delivery to cancer cells.
JP7884274B2Active Publication Date: 2026-07-03NEW YORK UNIV
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- NEW YORK UNIV
- Filing Date
- 2021-11-10
- Publication Date
- 2026-07-03
AI Technical Summary
Technical Problem
Current therapies for KRas protein-mutated cancers, such as lung, pancreatic, and colon cancer, are ineffective due to toxicity from off-target effects, and there is a need for targeted drug delivery systems that minimize such side effects.
Method used
Development of unbound protein-drug conjugates comprising a fibronectin type III (FN3) domain connected via an amino acid linker to a pharmaceutically active or diagnostic portion, which selectively targets macropinocytosis for targeted delivery to cancer cells.
Benefits of technology
The conjugates achieve selective targeting and increased efficacy in KRas-mutated cancer cells with reduced toxicity to non-target tissues, enhancing treatment specificity and safety.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007884274000006 
Figure 0007884274000007 
Figure 0007884274000008
Abstract
The present disclosure relates to pharmaceutical and diagnostic compositions comprising macropinocytosis-selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain linked to a pharmaceutically active or diagnostic moiety. The present disclosure also relates to methods of treatment and diagnosis comprising administering to a subject in need thereof a pharmaceutical composition described herein. TIFF2023551388000007.tif63166
Need to check novelty before this filing date? Find Prior Art